Hu, Tianyan
Podmore, Bélène
Barnett, Rosemarie
Beier, Dominik
Galetzka, Wolfgang
Qizilbash, Nawab
Haeckl, Dennis
Weaver, Jessica
Boellinger, Timo
Mihm, Sarah
Petigara, Tanaz
Article History
Received: 31 August 2021
Accepted: 28 March 2022
First Online: 13 April 2022
Declarations
:
: All patient-level data in the InGef research database are de-identified to comply with German data protection regulations. Use of the study database for healthcare services research is therefore fully compliant with German federal law and, accordingly, Institutional Review Board or ethical approval for this study was not needed. Since this study was based on anonymized claims data, no informed consent of the patient was required.
: Not applicable.
: This research was sponsored and funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. OXON Epidemiology, an independent contract research organisation, was contracted to design and conduct the study in collaboration with WIG2. InGef acted as subcontractor and received funding from WIG2 for the execution of the study.